<i>GSTP1</i> CpG island hypermethylation as a molecular biomarker for prostate cancer

Nakayama, Masashi; Gonzalgo, Mark L.; Yegnasubramanian, Srinivasan; Lin, Xiaohui; Marzo, Angelo M. De; Nelson, William G.

doi:10.1002/jcb.10740

Cited by 184 publications

(122 citation statements)

References 74 publications

Supporting

Mentioning

118

Contrasting

Order By: Relevance

“…A variety of techniques to detect DNA with GSTP1 CpG island hypermethylation in prostatic tissues and bodily fluids have been described (9). We used the previously described restriction endonuclease quantitative PCR method (12).…”

Section: Methodsmentioning

confidence: 99%

“…GSTP1 encodes an enzyme that acts as a carcinogen detoxifier by catalyzing conjugation reactions with reduced glutathione (7). Somatic GSTP1 CpG island hypermethylation has been noted in >90% of prostate cancer tissues, whereas it has not been observed in the normal prostate (9). It is important to note that DNA with GSTP1 CpG island hypermethylation is rarely seen elsewhere in the body, occurring with significance only in cancers of the liver and breast (10).…”

mentioning

confidence: 99%

“…It is important to note that DNA with GSTP1 CpG island hypermethylation is rarely seen elsewhere in the body, occurring with significance only in cancers of the liver and breast (10). Recently, analyses of bodily fluids from men with prostate cancer have revealed DNA containing GSTP1 CpG island hypermethylation, suggesting a possible role for this epigenetic phenomenon as a novel biomarker for prostate cancer (8,9,11). Using a restriction endonuclease quantitative PCR -based strategy that is capable of detecting a single hypermethylated CpG island allele, we sought to further characterize DNA-harboring GSTP1 CpG island hypermethylation in the preoperative serum of men with prostate cancer and to determine its association with PSA progression in men with initially clinically localized disease following radical prostatectomy (12).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Bastian¹,

Palapattu²,

Lin³

et al. 2005

Clinical Cancer Research

Self Cite

190

120

View full text Add to dashboard Cite

Purpose: Hypermethylation of the CpG island at the promoter region of the P-class glutathione S-transferase gene (GSTP1) is the most common somatic genome abnormality in human prostate cancer. We evaluated circulating cell-free DNA GSTP1 CpG island hypermethylation as a prognostic biomarker in the serum of men with prostate cancer. Experimental Design: Prostate cancer DNA GSTP1 CpG island hypermethylation was detected using a restriction endonuclease quantitative PCR technique. We analyzed preoperative serum from 85 men with clinically localized prostate cancer treated with radical prostatectomy and from 35 men with a negative prostate biopsy. We then assayed preoperative serum from a data set of 55 pairs of men with clinically localized prostate cancer treated with radical prostatectomy, matched for Gleason score, comprising 55 men suffering prostate-specific antigen (PSA) recurrence (median, 2 years) and 55 men who were free of disease at last follow-up (median, 3 years). The association of serum GSTP1 CpG island hypermethylation and PSA recurrence was determined. Results: Circulating cell-free DNA with GSTP1 CpG island hypermethylation was not detected in the serum of men with a negative prostate biopsy but was detected in 12% of men with clinically localized disease and 28% of men with metastatic cancer (P = 0.003). In the matched data set, eight men (15%) who developed PSA recurrence were positive for DNA with GSTP1 CpG hypermethylation, whereas no patient who was free of disease was positive for GSTP1 CpG island hypermethylation (McNemar test, m 2 = 6.1, P = 0.01). In a multivariable analysis that accounted for recognized prognostic factors, the presence of serum DNA with GTSP1 CpG island hypermethylation was the most significant predictor of PSA recurrence (hazard ratio, 4.4; 95% confidence interval, 2.2, 8.8; P < 0.001).Conclusion: Our study suggests that GSTP1 CpG island hypermethylation may be an important DNA-based prognostic serum biomarker for prostate cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Bastian¹,

Palapattu²,

Lin³

et al. 2005

Clinical Cancer Research

Self Cite

190

120

View full text Add to dashboard Cite

show abstract

“…We were initially alerted to a potential problem involving GC bias when GSTP1, which is highly methylated at its CpG islandassociated promoter in prostate cancer and is unmethylated in normal cells (Song et al 2002;Nakayama et al 2004), showed little differential enrichment at the probe-level on the Affymetrix promoter tiling arrays after MeDIP enrichment and WGA of prostate cancer (LNCaP) and normal prostate epithelial cells (PrECs) (see Supplemental Fig. 3A; Coolen et al 2010).…”

Section: Medip and Mbdcap Enrich Different Fractions Of The Genome Bamentioning

confidence: 99%

Evaluation of affinity-based genome-wide DNA methylation data: Effects of CpG density, amplification bias, and copy number variation

Robinson

Stirzaker²,

Statham³

et al. 2010

Genome Res.

113

103

View full text Add to dashboard Cite

DNA methylation is an essential epigenetic modification that plays a key role associated with the regulation of gene expression during differentiation, but in disease states such as cancer, the DNA methylation landscape is often deregulated. There are now numerous technologies available to interrogate the DNA methylation status of CpG sites in a targeted or genome-wide fashion, but each method, due to intrinsic biases, potentially interrogates different fractions of the genome. In this study, we compare the affinity-purification of methylated DNA between two popular genome-wide techniques, methylated DNA immunoprecipitation (MeDIP) and methyl-CpG binding domain-based capture (MBDCap), and show that each technique operates in a different domain of the CpG density landscape. We explored the effect of whole-genome amplification and illustrate that it can reduce sensitivity for detecting DNA methylation in GC-rich regions of the genome. By using MBDCap, we compare and contrast microarray-and sequencing-based readouts and highlight the impact that copy number variation (CNV) can make in differential comparisons of methylomes. These studies reveal that the analysis of DNA methylation data and genome coverage is highly dependent on the method employed, and consideration must be made in light of the GC content, the extent of DNA amplification, and the copy number.

show abstract

“…Molecular markers could have important applications in staging and the clinical diagnosis breast cancer [33]. Their Usage for cancer staging and personalization of treatment in time of diagnosis can improve patient care [34].…”

Section: Stage Of Diseasementioning

confidence: 99%

Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker

Dehbid¹,

Aleyasin²,

Vaziri³

2016

J Mol Biomark Diagn

View full text Add to dashboard Cite

IntroductionCancer is abnormal cell divisions without control and ability to invade other tissues. Most cancers are named for the organ or type of cell in which they start [1]. Breast cancer is a type of cancer that starts in the breast tissue. The causes are unknown, although there are some evidence that epigenetic factors may be one of the risk factors for breast cancer [2].The modern definition of epigenetics is the study of heritable changes in gene expression that are not caused by changes in DNA sequence [3]. DNA methylation of the epigenetic mechanisms involved in numerous phenomena such as parental imprinting, Growth and embryonic differentiation, X Chromosome inactivation and inhibition of gene transcription [4][5][6]. The methyl group (CH 3 ) is transfered from S-adenosylmethionine (SAM) to CPG dinucleotide on the 5-carbon position of cytosine by methyltransferases [7]. DNA Methylation occurs in intragenic, intergenic, 5› gene upstream and 3› gene downstream regions, which create a pattern of DNA methylation in genome [8].Many studies have shown that methylation pattern abnormalities lead to the creation of cancer [9], and hypermethylation and hypomethylation of DNA happen in early and developing stages of various types of cancers. They can be considered as epigenetic biomarker of cancer in the human DNA [10,11]. In other words, cancer biomarker refers to indication of the presence of cancer in the body [12]. In cancer research and medicine, usage of biomarkers is including: Diagnosis (to help diagnose conditions, as in the case of identifying early stage cancers); Prognosis (to indicate how aggressive a condition is, as in the case of determining a patient's ability to fare in the absence of treatment); Prediction (to predict how well a patient will respond to treatment) [13].Genetics, epigenetics, proteomics and glycomics can be used for cancer biomarkers [12]. In this study, we examined the Microtubule-Associated Protein 9 (MAP9) gene methylation as an epigenetic biomarker of cancer. Human MAP9 gene is also called ASAP, which is located on chromosome 4q32.1 and on the negative strand DNA [14]. The gene encodes MAP9 protein that it's C-terminal is associated with α-tubulin at all phases of the cell cycle. MAP9 protein is required for spindle function, bipolar spindle assembly, mitotic progression, and cytokinesis. It may also serve to stabilize interphase microtubules [15][16][17].Accurate transfer of genetic information plays essential roles for the survival of living organisms. DNA damage is induced by endogenous or exogenous factors. The tumor suppressor protein p53 is a central regulator of cell cycle arrest and apoptosis in the response to genotoxic stress. The inappropriate p53 activation is prevented through a network of tight controls in unstressed cells. The p53 protein is rapidly stabilized AbstractBackground: Recent findings indicate epigenetic modifications as key factors in breast carcinogenesis. The abnormal methylation patterns of genes are among the consequences of epigenetic changes...

show abstract

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer

Cited by 184 publications

References 74 publications

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy

Evaluation of affinity-based genome-wide DNA methylation data: Effects of CpG density, amplification bias, and copy number variation

Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker

Contact Info

Product

Resources

About